AI Summary
✦ ClarthaValuation Metrics
Trading 0.3% above historical median. Valuation is rising — currently in the fair zone (z-score: +0.18). Confidence: 84%.
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
83.88
Current
84.74
Overvalued
91.55
Undervalued
73.30
5Y Average
52.87
Current
53.41
Overvalued
58.71
Undervalued
46.16
5Y Average
23.48
Current
23.76
Overvalued
26.08
Undervalued
20.50
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 166.5x Premium | +155% vs avg | -51.2% |
CONCORD BIOTECH LIMITED CONCORDBIOPharmaceuticals | +26.2% | 24.8% | 49.2x Undervalued | -25% vs avg | -13.1% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 38.5x Undervalued | -41% vs avg | +56.1% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.5x Undervalued | -33% vs avg | -23.9% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 28.1x Undervalued | -57% vs avg | +43.4% |
GUJARAT THEMIS BIOSYN LTD trades at a premium (84.7x vs peer avg 65.2x), implying higher growth or quality expectations from the Pharmaceuticals cohort. Peers include COHANCE LIFESCIENCES LTD, CONCORD BIOTECH LIMITED, AKUMS DRUGS AND PHARMA L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹44 CrJun 2026Latest net profit
₹11 CrJun 2026Latest EPS
₹1.02Jun 2026Net margin
48.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 50 | 40 | 39 | 42 | 39 | 35 | 40 | 38 | 36 | 42 | 43 | 44 | 44 |
| Expenses + | 26 | 23 | 21 | 21 | 20 | 19 | 21 | 22 | 22 | 21 | 22 | 25 | 23 |
| Operating Profit | 24 | 17 | 18 | 21 | 19 | 15 | 19 | 16 | 14 | 21 | 21 | 19 | 21 |
| OPM % | 47% | 42% | 46% | 50% | 48% | 44% | 48% | 42% | 39% | 49% | 49% | 44% | 48% |
| Other Income + | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 4 | 4 |
| Profit before tax | 24 | 17 | 18 | 21 | 18 | 14 | 17 | 16 | 12 | 19 | 17 | 14 | 15 |
| Tax % | 26% | 26% | 26% | 24% | 26% | 26% | 25% | 25% | 25% | 24% | 26% | 24% | 27% |
| Net Profit + | 18 | 13 | 13 | 16 | 13 | 11 | 13 | 12 | 9 | 14 | 12 | 11 | 11 |
| EPS in Rs | 1.63 | 1.15 | 1.19 | 1.46 | 1.21 | 0.97 | 1.19 | 1.10 | 0.83 | 1.31 | 1.14 | 1.00 | 1.02 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Results- Unaudited Standalone And Consolidated Financial Results For The Quarter Ended 30Th June 2026
Board Meeting Outcome for Outcome Of The Board Meeting Held On 07.08.2026